Plain-English translation of NCT07220460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing an investigational medication called to see how well it treats depression in people with bipolar I or II disorder. Researchers want to understand whether this medication is safe and tolerable when taken by mouth over a 26-week period. The trial will involve about 200 adults across 50 locations in the United States and Puerto Rico.
Bipolar disorder is a serious condition that affects millions of Americans, and depressive episodes during bipolar disorder can be particularly difficult to treat. This medication is being developed to offer a new treatment option for people experiencing these depressive episodes.
You likely qualify if…
You likely don't qualify if…
You will take oral capsules of the medication every day for 26 weeks, then attend regular clinic visits (approximately every 1–2 weeks) at a hospital or research site. At these visits, doctors will check your health through physical exams, blood tests, and questionnaires to monitor how well the medication works and watch for any side effects. After the 26-week treatment period ends, you will have a 30-day follow-up period where the research team will continue to check on your safety.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States